Clinical Trials

GastrointestinalGynecologic

199 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms

NCT07038369 2026-03-17

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

BreastGenitourinaryGynecologic

134 enrolled

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03519230 2026-03-16

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

224 enrolled

Ovarian Neoplasms

NCT03842982 2026-03-16

CHIPPI

362 enrolled

Ovarian Neoplasms

NCT06003231 2026-03-16

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

GynecologicHead & NeckThoracic

120 enrolled

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT06607185 2026-03-13

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

GastrointestinalGynecologicThoracic

750 enrolled

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT03586661 2026-03-11

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

31 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Disease Progression

NCT02655016 2026-03-10

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

733 enrolled 21 charts 2 FDA

Ovarian Neoplasms

NCT04931342 2026-03-10

BOUQUET

176 enrolled

Ovarian Neoplasms

NCT00515372 2026-03-09

Depression Treatment and Screening in Ovarian Cancer Patients

409 enrolled

Depression, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02194387 2026-03-09

Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members

BreastGastrointestinalGynecologicLymphoidOther hematologic neoplasm

337 enrolled

Breast Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Fatigue, Ovarian Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Overweight

NCT05116189 2026-03-09

KEYNOTE-B96

643 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05677048 2026-03-09

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention

BreastGastrointestinalGynecologic

205 enrolled

Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ovarian Neoplasms, Pancreatic Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome

NCT02568267 2026-03-06

STARTRK-2

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

534 enrolled 1 FDA

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT04454450 2026-03-06

Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer

10 enrolled

Ovarian Neoplasms

NCT01970722 2026-03-05

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

40 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02345265 2026-03-05

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

70 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Phase 2/3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02502266 2026-03-05

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

582 enrolled 21 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06028932 2026-03-05

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

20 enrolled

Phase 1/2 Active not recruiting

Ovarian Neoplasms

NCT05180474 2026-03-03

GEN1047 for Solid Tumors - First in Human (FIH) Trial

179 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT04884360 2026-03-02

MONO-OLA1

366 enrolled

Ovarian Neoplasms

NCT04742075 2026-02-27

DOVACC

188 enrolled

Ovarian Neoplasms

NCT05891171 2026-02-27

ARC-25

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

40 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT06240598 2026-02-27

A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy

10 enrolled

Phase EARLY_PHASE1 Active not recruiting

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT03943173 2026-02-25

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

15 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05601752 2026-02-25

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

66 enrolled

Phase 1/2 Active not recruiting

Ovarian Neoplasms

NCT02264678 2026-02-20

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

357 enrolled

Ovarian Neoplasms

NCT04258813 2026-02-20

ONE TEAM